NASDAQ : ORKA

Oruka Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 96.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.41B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Details

NameOruka Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees68
Founded2004
CeoLawrence Klein
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS6876041087
Cusip687604108
Cik0000907654
Sic2834

Key executives

NameTitle
Dr. Lawrence Otto Klein Ph.D.President, Chief Executive Officer and Director
Paul T. QuinlanGeneral Counsel and Secretary
Dr. Joana Goncalves M.D.Chief Medical Officer
Arjun Agarwal CPASenior Vice President of Finance and Treasurer
Laura SandlerChief Operating Officer
Alan LadaVice President of IR and Capital Markets
Christopher FinchSenior Vice President and Head of Business Development and Strategy
Dr. Rajiv PanwarSenior Vice President and Head of Chemistry, Manufacturing and Controls
Larry Todd EdwardsChief Commercial Officer

Contact

Address855 Oak Grove Avenue, Suite 100, Menlo Park, California 94025, United States
Phone650 606 7910
Websitehttps://orukatx.com